Nevirapine nanosuspensions: Stability, plasma compatibility and sterilization

Journal of Pharmaceutical Investigation

Volumn 42, Issue 5, 2012, Pages 257-269

  Shegokar, Ranjita ^a,b   Singh, Kamalinder K ^a  

^a SNDT WOMEN S UNIVERSITY   (India)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Instability; Lyophilization; Nanosuspension; Nevirapine; Parenteral delivery; Plasma compatibility; Sterilization

Indexed keywords

CRYOPROTECTIVE AGENT; LACTOSE; MALTODEXTRIN; MANNITOL; NEVIRAPINE; TREHALOSE;

ADSORPTION; ARTICLE; BLOOD COMPATIBILITY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; DRUG RELEASE; DRUG STABILITY; DRY POWDER; FREEZE DRYING; INSTRUMENT STERILIZATION; MICROSCOPY; NANOSUSPENSION; PRIORITY JOURNAL; RADIATION STERILIZATION; SPRAY DRYING;

EID: 84874796801     PISSN: 20935552     EISSN: 20936214     Source Type: Journal    
DOI: 10.1007/s40005-012-0039-y     Document Type: Article

References (24)

1. Al Shaal L, Shegokar R, Muller RH (2011) Production and characterization of antioxidant apigenin nanocrystals as a novel UV skin protective formulation. Int J Pharm 420(1): 133-140.
2. Ambrus R, Kocbek P, Kristl J, Sibanc R, Rajko R, Szabo-Revesz P (2009) Investigation of preparation parameters to improve the dissolution of poorly water-soluble meloxicam. Int J Pharm 381(2): 153-159.
3. Aramwit P, Kerdcharoen T, Qi H (2006) In vitro plasma compatibility study of a nanosuspension formulation. PDA J Pharm Sci Technol 60(4): 211-217.
4. Beirowski J, Inghelbrecht S, Arien A, Gieseler H (2011a) Freeze-drying of nanosuspensions, 1: freezing rate versus formulation design as critical factors to preserve the original particle size distribution. J Pharm Sci 100(5): 1958-1968.
5. Beirowski J, Inghelbrecht S, Arien A, Gieseler H (2011b) Freeze drying of nanosuspensions, 2: the role of the critical formulation temperature on stability of drug nanosuspensions and its practical implication on process design. J Pharm Sci. doi: 10. 1002/jps. 22634.
6. Beirowski J, Inghelbrecht S, Arien A, Gieseler H (2012) Freeze-drying of nanosuspensions, part 3: investigation of factors compromising storage stability of highly concentrated drug nanosuspensions. J Pharm Sci 101(1): 354-362.
7. Chaubal MV, Popescu C (2008) Conversion of nanosuspensions into dry powders by spray drying: a case study. Pharm Res 25(10): 2302-2308.
8. Dave R, Patel R, Patel J, Chauhan H (2012) Effect of cryoprotectant on lyophilisation of doxorubicin-HCl loaded chitosan nanoparticles. Int J Pharm Life Sci 3(6): 1769-1772.
9. Dusanter A, Saleh K, Guigon P, (2008) Formulation of highly concentrated suspensions for spray drying in a fluidized bed. KONA Powder Part J 26.
10. Gianfrancesco A, Turchiuli C, Dumoulin E (2008) Powder agglomeration during the spray-drying process: measurements of air properties. Dairy Sci Technol 88(1): 53-64.
11. Hubalek Z (2003) Protectants used in the cryopreservation of microorganisms. Cryobiology 46(3): 205-229.
12. Jain S, Malyala P, Pallaoro M, Giuliani M, Petersen H, O'Hagan DT, Singh M (2011) A two-stage strategy for sterilization of poly(lactide-co-glycolide) particles by gamma-irradiation does not impair their potency for vaccine delivery. J Pharm Sci 100(2): 646-654.
13. Kayaert P, Anné M, van den Mooter G (2011) Bead layering as a process to stabilize nanosuspensions: influence of drug hydrophobicity on nanocrystal reagglomeration following in vitro release from sugar beads. J Pharm Pharmacol 63: 1446-1453.
14. Knight SC, Farrant J, McGann LE (1977) Storage of human lymphocytes by freezing in serum alone. Cryobiology 14(1): 112-115.
15. Koziara JM, Oh JJ, Akers WS, Ferraris SP, Mumper RJ (2005) Blood compatibility of cetyl alcohol/polysorbate-based nanoparticles. Pharm Res 22(11): 1821-1828.
16. Manju S, Sreenivasan K (2012) Gold nanoparticles generated and stabilized by water soluble curcumin-polymer conjugate: blood compatibility evaluation and targeted drug delivery onto cancer cells. J Colloid Interface Sci 368(1): 144-151.
17. Mitri K, Shegokar R, Gohla S, Anselmi C, Muller RH (2011) Lutein nanocrystals as antioxidant formulation for oral and dermal delivery. Int J Pharm 420(1): 141-146.
18. Müller RH, Böhm BHL, Grau MJ (2000) Nanosuspensions-a formulation approach for poorly soluble and poorly bioavailable drugs. In: Wise DL (ed) Handbook of pharmaceutical controlled release. Marcel Dekker, New York, pp 345-357.
19. Na GC, Stevens HJ, Yuan BO, Rajagopalan N (1999) Physical stability of ethyl diatrizoate nanocrystalline suspension in steam sterilization. Pharm Res 16(4): 569-574.
20. Nash RA (1972) Parenteral suspensions. Bull Parenter Drug Assoc 26(2): 91-94.
21. Nounou MM, Nawal LK, Khalil K (2005) Influence of different sugar cryoprotectants on the stability and physio-chemical characteristics of freeze dried 5-fluorouracil plurilamillar vesicles. DARU 13(4).
22. Schiffter H, Condliffe J, Vonhoff S (2010) Spray-freeze-drying of nanosuspensions: the manufacture of insulin particles for needle-free ballistic powder delivery. Interface 7: S483-S500.
23. Shegokar R, Müller RH (2010) Nanocrystals: industrially feasible multifunctional formulation technology for poorly soluble actives. Int J Pharm 399(1-2): 129-139.
24. Stark B, Pabst G, Prassl R (2010) Long-term stability of sterically stabilized liposomes by freezing and freeze-drying: effects of cryoprotectants on structure. Eur J Pharm Sci 41(3-4): 546-555.